Contemporary role of advanced imaging for bladder cancer staging

Urologic Oncology: Seminars and Original Investigations

Volumn 34, Issue 3, 2016, Pages 124-133

  Rais Bahrami, Soroush ^a,b   Pietryga, Jason A ^b   Nix, Jeffrey W ^a  

^a Hugh Kaul Human Genetics Building   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

MRI; PET; Transitional cell carcinoma; Urothelial carcinoma

Indexed keywords

CONTRAST MEDIUM;

ADVERSE OUTCOME; BLADDER CANCER; BLADDER CARCINOMA; CANCER PATIENT; CANCER STAGING; CLINICAL DECISION MAKING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; GOLD STANDARD; HUMAN; LYMPH NODE METASTASIS; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PATIENT COUNSELING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VISCERAL METASTASIS; BLADDER TUMOR; CLASSIFICATION; PATHOLOGY; PROCEDURES;

DIAGNOSTIC IMAGING; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 84958120330     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.08.018     Document Type: Review

References (76)

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015, 65:5-29.
2. Donat S.M. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 2003, 30:765-776.
3. Grossman H.B., Gomella L., Fradet Y., Morales A., Presti J., Ritenour C., et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007, 178:62-67.
4. Fradet Y., Grossman H.B., Gomella L., Lerner S., Cookson M., Albala D., et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007, 178:68-73. [discussion 73].
5. Daneshmand S., Schuckman A.K., Bochner B.H., Cookson M.S., Downs T.M., Gomella L.G., et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol 2014, 11:589-596.
6. Zheng C., Lv Y., Zhong Q., Wang R., Jiang Q. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int 2012, 110:E680-E687.
7. Goh A.C., Tresser N.J., Shen S.S., Lerner S.P. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology 2008, 72:133-137.
8. Rais-Bahrami S., Levinson A.W., Fried N.M., Lagoda G.A., Hristov A., Chuang Y., et al. Optical coherence tomography of cavernous nerves: a step toward real-time intraoperative imaging during nerve-sparing radical prostatectomy. Urology 2008, 72:198-204.
9. Chang T.C., Liu J.J., Hsiao S.T., et al. Interobserver agreement of confocal laser endomicroscopy for bladder cancer. J Endourol 2013, 27:598-603.
10. Barman I., Dingari N.C., Singh G.P., et al. Selective sampling using confocal Raman spectroscopy provides enhanced specificity for urinary bladder cancer diagnosis. Anal Bioanal Chem 2012, 404:3091-3099.
11. Bach T., Muschter R., Herrmann T.R., Knoll T., Scoffone C.M., Laguna M.P., et al. Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future perspectives. BJU Int 2015, 115:14-23.
12. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999, 162:74-76.
13. Dobruch J., Borówka A., Herr H.W. Clinical value of transurethral second resection of bladder tumor: systematic review. Urology 2014, 84:881-885.
14. Herr H.W., Donat S.M. Reduced bladder tumour recurrence rate associated with narrow-band imaging surveillance cystoscopy. BJU Int 2011, 107:396-398.
15. Herr H.W., Donat S.M. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int 2008, 102:1111-1114.
16. Kamat A.M., Hegarty P.K., Gee J.R., Clark P.E., Svatek R.S., Hegarty N., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 2013, 63:4-15.
17. Kim J.K., Park S.Y., Ahn H.J., Kim C.S., Cho K.S. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 2004, 231:725-731.
18. Watanabe H., Kanematsu M., Kondo H., Goshima S., Tsuge Y., Onozuka M., et al. Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value?. Am J Roentgenol 2009, 192:1361-1366.
19. Kundra V., Silverman P.M. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. Am J Roentgenol 2003, 180:1045-1054.
20. Shariat S.F., Palapattu G.S., Karakiewicz P.I., Rogers C.G., Vazina A., Bastian P.J., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007, 51:137-149. [discussion 149-51].
21. Barentsz J., Engelbrecht M., Witjes J., De la Rosette J., Van der Graaf M. MR imaging of the male pelvis. Eur Radiol 1999, 9:1722-1736.
22. Tritschler S., Mosler C., Straub J., et al. Staging of muscle-invasive bladder cancer: can computerized tomography help us to decide on local treatment?. World J Urol 2012, 30:827-831.
23. Paik M.L., Scolieri M.J., Brown S.L., Spirnak J.P., Resnick M.I. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 2000, 163:1693-1696.
24. Gray P.J., Lin C.C., Jemal A., Shipley W.U., Fedewa S.A., Kibel A.S., et al. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys 2014, 88:1048-1056.
25. Baltaci S., Resorlu B., Yagci C., Turkolmez K., Gogus C., Beduk Y. Computerized tomography for detecting perivesical infiltration and lymph node metastasis in invasive bladder carcinoma. Urol Int 2008, 81:399-402.
26. Saokar A., Islam T., Jantsch M., Saksena M.A., Hahn P.F., Harisinghani M.G. Detection of lymph nodes in pelvic malignancies with Computed Tomography and Magnetic Resonance Imaging. Clin Imaging 2010, 34:361-366.
27. Jeong I.G., Hong S., You D., Hong J.H., Ahn H., Kim C.S. FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy. Ann Surg Oncol 2015, 22(9):3150-3156.
28. 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 2006, 47:938-944.
29. Saokar A., Gee M.S., Islam T., Mueller P.R., Harisinghani M.G. Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10. Clin Imaging 2010, 34:448-452.
30. Fortuin A.S., Meijer H., Thompson L.C., Witjes J.A., Barentsz J.O. Ferumoxtran-10 ultrasmall superparamagnetic iron oxide-enhanced diffusion-weighted imaging magnetic resonance imaging for detection of metastases in normal-sized lymph nodes in patients with bladder and prostate cancer: do we enter the era after extended pelvic lymph node dissection?. Eur Urol 2013, 64:961-963. [discussion 963].
31. Giannarini G., Petralia G., Thoeny H.C. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 2012, 61:326-340.
32. Papalia R., Simone G., Grasso R., Augelli R., Faiella E., Guaglianone S., et al. Diffusion-weighted magnetic resonance imaging in patients selected for radical cystectomy: detection rate of pelvic lymph node metastases. BJU Int 2012, 109:1031-1036.
33. Shvarts O., Han K.R., Seltzer M., Pantuck A.J., Belldegrun A.S. Positron emission tomography in urologic oncology. Cancer Control 2002, 9:335-342.
34. Bouchelouche K., Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 2008, 179:34-45.
35. Harkirat S., Anand S., Jacob M. Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers. Indian J Radiol Imaging 2010, 20:13-19.
36. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 2007, 48:764-770.
37. 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 2006, 47:938-944.
38. 11C choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol 2012, 61:1031-1038.
39. 11C-choline. Clin Nucl Med 2012, 37:e67-e72.
40. 11C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol Imaging Biol 2012, 14:245-251.
41. 11C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol 2012, 81:4131-4137.
42. Ahlström H., Malmström P.U., Letocha H., Andersson J., Långström B., Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996, 37:180-185.
43. Swinnen G., Maes A., Pottel H., Vanneste A., Billiet I., Lesage K., et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 2010, 57:641-647.
44. Lodde M., Lacombe L., Friede J., Morin F., Saourine A., Fradet Y. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int 2010, 106:658-663.
45. 18F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009, 27:4314-4320.
46. Goodfellow H., Viney Z., Hughes P., Rankin S., Rottenberg G., Hughes S., et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int 2014, 114:389-395.
47. 18F-fluoride PET/CT. J Nucl Med 2004, 45:272-278.
48. 18F-fluoride PET on intended management of patients with cancers other than prostate cancer: results from the national oncologic PET registry. J Nucl Med 2014, 55:1054-1061.
49. 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma. Clin Nucl Med 2013, 38:616-621.
50. Bouchelouche K., Capala J. "Image and treat": an individualized approach to urological tumors. Curr Opin Oncol 2010, 22:274-280.
51. Orlova A., Tran T.A., Ekblad T., Karlström A.E., Tolmachev V. 186Re-maSGS-ZHER2: 342, a potential affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging 2010, 37:260-269.
52. Rais-Bahrami S., Siddiqui M.M., Turkbey B., Stamatakis L., Logan J., Hoang A.N., et al. Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol 2013, 190:1721-1727.
53. Rais-Bahrami S., Turkbey B., Grant K.B., Pinto P.A., Choyke P.L. Role of multiparametric magnetic resonance imaging in the diagnosis of prostate cancer. Curr Urol Rep 2014, 15:387.
54. Ramamurthy N.K., Moosavi B., McInnes M.D., Flood T.A., Schieda N. Multiparametric MRIof solid renal masses: pearls and pitfalls. Clin Radiol 2015, 70:304-316.
55. Haas R.J., Steyvers M.J., Fütterer J.J. Multiparametric MRIof the bladder: ready for clinical routine?. Am J Roentgenol 2014, 202:1187-1195. de.
56. Tekes A., Kamel I.R., Imam K., Chan T.Y., Schoenberg M.P., Bluemke D.A. MR imaging features of transitional cell carcinoma of the urinary bladder. Am J Roentgenol 2003, 180:771-777.
57. Beer A., Saar B., Rummeny E.J. Tumors of the urinary bladder: technique, current use, and perspectives of MR and CT cystography. Abdom Imaging 2003, 28:868-876.
58. Lämmle M., Beer A., Settles M., Hannig C., Schwaibold H., Drews C. Reliability of MR imaging-based virtual cystoscopy in the diagnosis of cancer of the urinary bladder. Am J Roentgenol 2002, 178:1483-1488.
59. Beer A., Saar B., Zantl N., Link T.M., Roggel R., Hwang S.L., et al. MR cystography for bladder tumor detection. Eur Radiol 2004, 14:2311-2319.
60. Takeuchi M., Sasaki S., Ito M., Okada S., Takahashi S., Kawai T., et al. Urinary bladder cancer: diffusion-weighted MR imaging-accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009, 251:112-121.
61. Matsuki M., Inada Y., Tatsugami F., Tanikake M., Narabayashi I., Katsuoka Y. Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results. Eur Radiol 2007, 17:201-204.
62. El-Assmy A., Abou-El-Ghar M.E., Mosbah A., et al. Bladder tumour staging: comparison of diffusion-and T2-weighted MR imaging. Eur Radiol 2009, 19:1575-1581.
63. Kobayashi S., Koga F., Kajino K., et al. Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. J Magn Reson Imaging 2014, 39:172-178.
64. Daneshmand S., Ahmadi H., Huynh L.N., Dobos N. Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. Urology 2012, 80:1313-1318.
65. Tekes A., Kamel I., Imam K., et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. Am J Roentgenol 2005, 184:121-127.
66. Barentsz J.O., Jager G.J., van Vierzen P.B., Witjes J.A., Strijk S.P., Peters H., et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology 1996, 201:185-193.
67. Heesakkers R.A., Hövels A.M., Jager G.J., van den Bosch H.C., Witjes J.A., Raat H.P., et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008, 9:850-856.
68. Thoeny H.C., Triantafyllou M., Birkhaeuser F.D., Froehlich J.M., Tshering D.W., Binser T., et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009, 55:761-769.
69. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
70. Deserno W.M., Harisinghani M.G., Taupitz M., et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004, 233:449-456.
71. Birkhäuser F.D., Studer U.E., Froehlich J.M., et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 2013, 64:953-960.
72. Bashir M.R., Bhatti L., Marin D., Nelson R.C. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging 2015, 41:884-898.
73. Kobayashi S., Koga F., Kajino K., Yoshita S., Ishii C., Tanaka H., et al. Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. J Magn Reson Imaging 2014, 39:172-178.
74. Bernstein J.M., Homer J.J., West C.M. Dynamic contrast-enhanced magnetic resonance imaging biomarkers in head and neck cancer: potential to guide treatment? A systematic review. Oral Oncol 2014, 50:963-970.
75. Nguyen H.T., Jia G., Shah Z.K., Pohar K., Mortazavi A., Zynger D.L., et al. Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. J Magn Reson Imaging 2015, 41:1374-1382.
76. Mertens L.S., Fioole-Bruining A., van Rhijn B.W., Kerst J.M., Bergman A.M., Vogel W.V., et al. FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer. J Urol 2013, 189:1687-1691.